NASA selected 12 companies to provide services to its ISS program and five hail from just down the road of the program. Photo via nasa.gov

NASA has tapped a dozen companies to work on services for the International Space Station Program, and five come from the greater Houston region.

Houston-based Aegis Aerospace Inc., Cimarron Software Services, JES Tech, and Oceaneering were are all admitted to the program, as was Webster-based Leidos. The companies, along with the other seven selected, will provide research, engineering, and/or mission integration services to the ISS.

The program, which is based at NASA’s Johnson Space Center in Houston, is supported by a $478 million Research, Engineering & Mission Integration Services-2 or REMIS-2 contract, according to NASA.

The other selected companies are:

  • Axient Corp, based in Huntsville, Alabama
  • Consolidated Safety Services, based in Exploration Park, Florida
  • KBR Wyle, based in Fulton, Maryland
  • Metis, based in Albuquerque, New Mexico
  • Tec-Masters, based in Huntsville
  • Teledyne Brown Engineering, based in Huntsville
  • University of Alabama at Birmingham, Alabama

"The companies will provide spaceflight, ground hardware and software, sustaining engineering functions and services, payload facility integration, and research mission integration operations services," reads a NASA news release. "The majority of the work will take place at contractor facilities across the country. Services also may be required at other NASA centers, contractor or subcontractor locations, or vendor facilities as requirements warrant."

Each of the selected companies will receive a "multiple-award, indefinite-quantity contract with firm-fixed price and cost-plus-fixed-fee task orders." The contract officially began January 12 and extends through Sept. 30, 2030, with an option to extend through Sept. 30, 2032.

Half of the selected companies — Aegis, Cimarron, Consolidated Safety Services, JES Tech, Metis, and Tec-Masters — are small businesses and were selected as a part of the contract's small business reserve.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.